Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence on LinkedIn:
”This marks the end of availability for the only specific reversal agent for apixaban and rivaroxaban in the U.S., shifting reliance back to non-specific options like PCCs or supportive care for managing FXa inhibitor-associated bleeds.”
Qutoing Beyondsight Intelligence‘s post:
”FDA Issues Safety Update on Andexxa — U.S. Withdrawal Announced
The FDA has determined that postmarketing safety data for Andexxa (andexanet alfa), the anticoagulation reversal agent, show that serious thromboembolic risks outweigh its clinical benefits.
AstraZeneca will voluntarily withdraw Andexxa from the U.S. market, with availability ending December 22, 2025.
Key Points:
• Granted accelerated approval in 2018 for reversal of rivaroxaban and apixaban in life-threatening or uncontrolled bleeding
• Approval included a Boxed Warning for thromboembolic risk
• Postmarketing evidence, including ANNEXA-I, raised concerns around thrombotic events and mortality
Why It Matters:
• Highlights how real-world and confirmatory data can fundamentally shift benefit–risk assessments
• Reinforces the FDA’s scrutiny of accelerated approvals when safety signals emerge
• Leaves a gap in anticoagulation reversal options, impacting critical care decision-making
Key Takeaway:
Andexxa’s U.S. withdrawal underscores the power of post-approval evidence in reshaping regulatory outcomes—and the importance of long-term safety surveillance for high-risk biologics.
Follow our page for more such updates.
News Source.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers